Vidović D, Toral J I
Discovery Research, Hoffmann-La Roche Inc., Nutley, NJ 07110-1199, USA.
Cancer Lett. 1998 Jun 19;128(2):127-35. doi: 10.1016/s0304-3835(98)00034-2.
The human major histocompatibility complex (MHC) class II molecule-specific monoclonal antibody (mAb) 8D1 can induce apoptosis of tumor cells expressing HLA-DR molecules on their surface. This effect is associated with a cross-linking of HLA-DR, since monovalent Fab fragments of 8D1 cannot mediate cytotoxicity unless they are anchored to a solid support. Anti-neoplastic activity of 8D1 is highly selective, i.e. the mAb affects neither the viability nor the function of non-malignant HLA-DR+ cells. These findings raise the possibility of a selective antibody-based anti-tumor therapy of class II positive blood cell neoplasm.